8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) April 23, 2008

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802	22-0760120
(Commission File Number)	(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey	07417-1880
(Address of Principal Executive Offices)	(Zip Code)

(201) 847-6800

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02      RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On April 23, 2008, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for the fiscal quarter ending March 31, 2008. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (GAAP), as follows:

• Revenues. We present international and total company revenue growth rates at constant foreign exchange rates. We believe that presenting revenue growth rates at constant foreign exchange rates allows investors to view the underlying operating results of BD and of its segments without the impact of fluctuations in foreign currency exchange rates, thereby facilitating comparisons to prior periods.

• Operating Income. We present BD’s operating income, both alone and as a percentage of revenues, for the first six months of fiscal year 2007 after excluding the impact of the in-process research and development (“R&D”) charge relating to our acquisition of TriPath Imaging, Inc. (“TriPath”). This charge affected reported operating income for the period, but is not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of operating income are more indicative of BD’s underlying performance, and allow investors to better understand BD’s comparative operating performance for the period.

• Effective Tax Rate. We present the effective tax rate for the first six months of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to our acquisition of TriPath. This charge, which is not considered part of ordinary operations by management and is not tax deductible, caused our effective tax rate for the fiscal year to be higher than it otherwise would have been. Management believes that this adjusted measure of our effective tax rate is more indicative of BD’s underlying results, and allows investors to better understand BD’s comparative effective tax rate for the period.

• Income from Continuing Operations. We present BD’s income from continuing operations, both alone and as a percentage of revenues, for the first six months of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to the TriPath acquisition. This item affected reported income from continuing operations for the period, but is not considered by management to be part of ordinary operations.
  Accordingly, management believes that these adjusted measures of income from continuing operations are more indicative of BD’s underlying performance, and allow investors to better understand BD’s comparative income from continuing operations for the period.

• Earnings Per Share. We present earnings per share from continuing operations for the first six months of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to the TriPath acquisition, and for the 2007 fiscal year after excluding the impact of the in-process R&D charges relating to the TriPath acquisition and our acquisition of Plasso Technology, Ltd. These charges caused reported earnings per share for such periods to be lower than they otherwise would have been, although these charges are not considered by management to be part of ordinary operations. We believe that measures of earnings per share that are adjusted for the impact of these charges is more indicative of BD’s underlying performance and allow investors to more easily compare BD’s results for the period to other periods.

BD’s management uses each of these non-GAAP measures in its own evaluation of BD’s performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD’s financial results. Management believes the non-GAAP results provide a reasonable measure of BD’s underlying performance before the effects of items that are considered by management to be outside of BD’s underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD’s results.

ITEM 9.01     FINANCIAL STATEMENTS AND EXHIBITS.

 Exhibits. — Exhibit 99.1 Press release dated April 23, 2008, which is furnished pursuant to Item 2.02.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas

        Dean J. Paranicas
        Vice President, Corporate
        Secretary and Public Policy

Date: April 23, 2008

INDEX TO EXHIBITS

Exhibit Number	Description of Exhibits
99.1	Press release dated April 23, 2008, which is furnished pursuant to Item 2.02.

EX-99.1

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com

News Release

Contact:
Patricia A. Spinella, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369

BD ANNOUNCES RESULTS FOR SECOND FISCAL QUARTER

Earnings per share from continuing operations increased 18% to $1.09;

Company raises earnings guidance for full fiscal year

Franklin Lakes, NJ (April 23, 2008) – BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of $1.747 billion for the second fiscal quarter ended March 31, 2008, representing an increase of 11 percent over the prior year period. This quarter’s revenue growth rate reflects the favorable impact on all segments from foreign currency translation, which overall is estimated to account for 5 percentage points of the increase in quarterly revenues.

"We are pleased with our strong results, which were once again driven by solid company-wide revenue growth and disciplined spending controls that more than offset the headwind we have been facing as a result of increasing raw material costs," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "Accordingly, we are increasing our earnings guidance for the full year."

Second Quarter and Six-Month Period of Fiscal Year 2008 and 2007 Earnings

Reported diluted earnings per share from continuing operations of $1.09 for the second quarter increased by 18 percent over diluted earnings per share from continuing operations of 92 cents for the second fiscal quarter of 2007. For the six-month period ending March 31, 2008, reported diluted earnings per share from continuing operations were $2.16. For the six-month period ending March 31, 2007, reported diluted earnings per share from continuing operations were $1.44. The following analysis (Table 1) of diluted earnings per share from continuing operations for the six-month periods ended March 31, 2008 and 2007 identifies the specified item that affects comparability of results between periods. As illustrated, diluted earnings per share from continuing operations of $2.16 for fiscal 2008 increased by 14 percent over comparable fiscal 2007 diluted earnings per share from continuing operations of $1.89, which exclude the specified item.

(Table 1)	Six Months Ended March 31,
	FY2008	FY2007	% Change
Diluted EPS from Continuing Operations:	$ 2.16	$ 1.44	50%
Specified Item:
In-Process Research and Development Charge(1)	-	0.45
Diluted EPS from Continuing Operations Excluding Specified Items:	$ 2.16	$ 1.89	14%

⁽¹⁾ Represents the effect on diluted earnings per share from continuing operations of the in-process research and development charge recorded in the first quarter of fiscal 2007 related to the TriPath acquisition.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $922 million, representing an increase of 9 percent from the prior year period. For the six-month period ended March 31, 2008, the BD Medical segment reported 10 percent revenue growth. Pharmaceutical Systems and Diabetes Care products led revenue growth in the segment.

In the BD Diagnostics segment, worldwide revenues for the quarter were $531 million, representing an increase of 12 percent from the prior year’s quarter. For the six-month period ended March 31, 2008, the BD Diagnostics segment reported 15 percent revenue growth. Sales of safety-engineered devices, TriPath products, and molecular testing systems, including GeneOhm, contributed to revenue growth.

In the BD Biosciences segment, worldwide revenues for the quarter were $294 million, representing an increase of 14 percent from the prior year’s quarter. For the six-month period ended March 31, 2008, the BD Biosciences segment reported 16 percent revenue growth. Demand for research instruments as well as clinical and research reagents continued to be the primary growth drivers.

Geographic Results

Second quarter revenues in the U.S. were $784 million, representing an increase of 4 percent over the prior year period. Revenues outside the U.S. were $963 million, representing an increase of 17 percent over the prior year period, with approximately 10 percentage points of the increase resulting from the favorable impact of foreign currency translation.

For the six-month period ended March 31, 2008, revenues in the U.S. were $1.574 billion, representing an increase of 7 percent over the prior year period. Revenues outside of the U.S. were $1.879 billion, representing an increase of 17 percent over the prior year period, with approximately 10 percentage points of the increase resulting from the favorable impact from foreign currency translation.

Fiscal 2008 Outlook for Full Year

The Company raised its guidance for full fiscal year 2008 diluted earnings per share from continuing operations to approximately 13 to 14 percent from approximately 11 to 13 percent over adjusted diluted earnings per share from continuing operations of $3.84 for the full fiscal year 2007. Reported

diluted earnings per share from continuing operations for the full fiscal year 2007 were $3.36, which included 48 cents for in-process research and development charges related to the TriPath and Plasso acquisitions. Excluding these charges, adjusted diluted earnings per share from continuing operations for the full fiscal year 2007 were $3.84.

Conference Call Information

A conference call regarding BD’s second fiscal quarter results and its expectations for the full fiscal year will be broadcast live on BD’s website, www.bd.com/investors, at 10:00 a.m. (ET) Wednesday, April 23, 2008. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 800-388-6197 (domestic) and 402-220-1115 (international), Conference ID: 7BDX, through the close of business on Wednesday, April 30, 2008.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

***

This press release, including the section entitled “Fiscal 2008 Outlook for Full Year,” contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

	Three Months Ended March 31,
		2008			2007		% Change
REVENUES	$	1,746,925		$	1,575,922		10.9
Cost of products sold		853,807			764,540		11.7
Selling and administrative		415,523			406,631		2.2
Research and development		96,034			86,687		10.8
TOTAL OPERATING COSTS
AND EXPENSES		1,365,364			1,257,858		8.5
OPERATING INCOME		381,561			318,064		20.0
Interest income		8,005			9,086		(11.9	)
Interest expense		(8,098	)		(11,686	)	(30.7	)
Other income, net		828			5,872		NM
INCOME FROM CONTINUING OPERATIONS BEFORE
INCOME TAXES		382,296			321,336		19.0
Income tax provision		106,661			85,797		24.3
INCOME FROM CONTINUING OPERATIONS		275,635			235,539		17.0
INCOME FROM DISCONTINUED OPERATIONS
NET OF INCOME TAX PROVISION OF
$347 AND $4,222, RESPECTIVELY		550			6,994		NM
NET INCOME	$	276,185		$	242,533		13.9
EARNINGS PER SHARE
Basic:
Income from continuing operations	$	1.13		$	0.96		17.7
Income from discontinued operations	$	-		$	0.03		NM
Net income	$	1.13		$	0.99		14.1
Diluted:
Income from continuing operations	$	1.09		$	0.92		18.5
Income from discontinued operations	$	-		$	0.03		NM
Net income	$	1.09		$	0.95		14.7
AVERAGE SHARES OUTSTANDING
Basic		244,869			245,418
Diluted		252,788			254,740
NM - Not Meaningful

Page 1

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

	Six Months Ended March 31,
		2008			2007		% Change
REVENUES	$	3,452,692		$	3,077,449		12.2
Cost of products sold		1,683,654			1,473,474		14.3
Selling and administrative		837,240			790,715		5.9
Research and development		187,561			166,627		12.6
Acquired in-process research and development		-			114,739		NM
TOTAL OPERATING COSTS
AND EXPENSES		2,708,455			2,545,555		6.4
OPERATING INCOME		744,237			531,894		39.9
Interest income		21,534			25,200		(14.5	)
Interest expense		(18,438	)		(24,555	)	(24.9	)
Other income, net		1,535			3,505		NM
INCOME FROM CONTINUING OPERATIONS BEFORE
INCOME TAXES		748,868			536,044		39.7
Income tax provision		202,337			169,454		19.4
INCOME FROM CONTINUING OPERATIONS		546,531			366,590		49.1
INCOME FROM DISCONTINUED OPERATIONS
NET OF INCOME TAX PROVISION OF
$734 AND $11,362, RESPECTIVELY		1,201			18,822		NM
NET INCOME	$	547,732		$	385,412		42.1
EARNINGS PER SHARE
Basic:
Income from continuing operations	$	2.23		$	1.49		49.7
Income from discontinued operations	$	-		$	0.08		NM
Net income (1)	$	2.24		$	1.57		42.7
Diluted:
Income from continuing operations	$	2.16		$	1.44		50.0
Income from discontinued operations	$	-		$	0.07		NM
Net income	$	2.16		$	1.51		43.0
AVERAGE SHARES OUTSTANDING
Basic		244,580			245,484
Diluted		253,288			255,178

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding

Page 2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
(Unaudited; Amounts in thousands, except per share data)

	Six Months Ended March 31, 2007
		As			TriPath		Excluding
		Reported			IPR&D (1)		Items
Operating Income	$	531,894		$	114,739	$	646,633
as a % of revenues		17.3	%				21.0	%
Income taxes		169,454			-		169,454
effective tax rate		31.6	%				26.0	%
Income from continuing operations		366,590			114,739		481,329
as a % of revenues		11.9	%				15.6	%
Diluted earnings per share
Income from continuing operations	$	1.44		$	0.45	$	1.89

(1) Represents the acquired in-process research and development charge of $114,739 related to the TriPath acquisition.

	Fiscal Year 2007
	As					Excluding
	Reported			IPR&D (2)		Items
Diluted earnings per share
Income from continuing operations	$	3.36	$	0.48	$	3.84

(2) Represents the acquired in-process research and development charges related to the TriPath and Plasso acquisitions.

Page 3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	Three Months Ended March 31,
		2008		2007	% Change
BD MEDICAL
United States	$	388,281	$	378,789	2.5
International		533,971		465,355	14.7
TOTAL	$	922,252	$	844,144	9.3
BD DIAGNOSTICS
United States	$	281,088	$	265,800	5.8
International		249,484		207,430	20.3
TOTAL	$	530,572	$	473,230	12.1
BD BIOSCIENCES
United States	$	114,581	$	109,429	4.7
International		179,520		149,119	20.4
TOTAL	$	294,101	$	258,548	13.8
TOTAL REVENUES
United States	$	783,950	$	754,018	4.0
International		962,975		821,904	17.2
TOTAL	$	1,746,925	$	1,575,922	10.9

Page 4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	Six Months Ended March 31,
		2008		2007	% Change
BD MEDICAL
United States	$	795,772	$	760,596	4.6
International		1,035,764		909,795	13.8
TOTAL	$	1,831,536	$	1,670,391	9.6
BD DIAGNOSTICS
United States	$	560,576	$	508,699	10.2
International		492,747		406,932	21.1
TOTAL	$	1,053,323	$	915,631	15.0
BD BIOSCIENCES
United States	$	217,653	$	205,349	6.0
International		350,180		286,078	22.4
TOTAL	$	567,833	$	491,427	15.5
TOTAL REVENUES
United States	$	1,574,001	$	1,474,644	6.7
International		1,878,691		1,602,805	17.2
TOTAL	$	3,452,692	$	3,077,449	12.2

Page 5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31,
(Unaudited; Amounts in thousands)

	United States
		2008		2007	% Change
BD MEDICAL
Medical Surgical Systems	$	232,447	$	230,881	0.7
Diabetes Care		96,883		97,647	(0.8	)
Pharmaceutical Systems		52,779		44,370	19.0
Ophthalmic Systems		6,172		5,891	4.8
TOTAL	$	388,281	$	378,789	2.5
BD DIAGNOSTICS
Preanalytical Systems	$	140,674	$	131,937	6.6
Diagnostic Systems		140,414		133,863	4.9
TOTAL	$	281,088	$	265,800	5.8
BD BIOSCIENCES
Cell Analysis (1)	$	78,269	$	71,719	9.1
Discovery Labware		36,312		37,710	(3.7	)
TOTAL	$	114,581	$	109,429	4.7
TOTAL UNITED STATES	$	783,950	$	754,018	4.0

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

Page 6

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

	International
					% Change
		2008		2007	Reported	FX Neutral		FX Impact
BD MEDICAL
Medical Surgical Systems	$	248,269	$	216,459	14.7	5.5		9.2
Diabetes Care		90,577		73,544	23.2	11.7		11.5
Pharmaceutical Systems		181,660		164,442	10.5	(0.5	)	11.0
Ophthalmic Systems		13,465		10,910	23.4	14.0		9.4
TOTAL	$	533,971	$	465,355	14.7	4.5		10.2
BD DIAGNOSTICS
Preanalytical Systems	$	133,518	$	112,809	18.4	8.1		10.3
Diagnostic Systems		115,966		94,621	22.6	13.1		9.5
TOTAL	$	249,484	$	207,430	20.3	10.4		9.9
BD BIOSCIENCES
Cell Analysis (1)	$	141,452	$	116,494	21.4	11.4		10.0
Discovery Labware		38,068		32,625	16.7	6.5		10.2
TOTAL	$	179,520	$	149,119	20.4	10.4		10.0
TOTAL INTERNATIONAL	$	962,975	$	821,904	17.2	7.1		10.1

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

Page 7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

	Total
					% Change
		2008		2007	Reported	FX Neutral	FX Impact
BD MEDICAL
Medical Surgical Systems	$	480,716	$	447,340	7.5	3.0	4.5
Diabetes Care		187,460		171,191	9.5	4.6	4.9
Pharmaceutical Systems		234,439		208,812	12.3	3.6	8.7
Ophthalmic Systems		19,637		16,801	16.9	10.7	6.2
TOTAL	$	922,252	$	844,144	9.3	3.6	5.7
BD DIAGNOSTICS
Preanalytical Systems	$	274,192	$	244,746	12.0	7.3	4.7
Diagnostic Systems		256,380		228,484	12.2	8.3	3.9
TOTAL	$	530,572	$	473,230	12.1	7.8	4.3
BD BIOSCIENCES
Cell Analysis (1)	$	219,721	$	188,213	16.7	10.6	6.1
Discovery Labware		74,380		70,335	5.8	1.0	4.8
TOTAL	$	294,101	$	258,548	13.8	8.0	5.8
TOTAL REVENUES	$	1,746,925	$	1,575,922	10.9	5.6	5.3

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

Page 8

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31,
(Unaudited; Amounts in thousands)

	United States
		2008		2007	% Change
BD MEDICAL
Medical Surgical Systems	$	485,192	$	473,183	2.5
Diabetes Care		195,409		188,139	3.9
Pharmaceutical Systems		102,757		87,269	17.7
Ophthalmic Systems		12,414		12,005	3.4
TOTAL	$	795,772	$	760,596	4.6
BD DIAGNOSTICS
Preanalytical Systems	$	283,974	$	263,640	7.7
Diagnostic Systems		276,602		245,059	12.9
TOTAL	$	560,576	$	508,699	10.2
BD BIOSCIENCES
Cell Analysis (1)	$	145,629	$	133,551	9.0
Discovery Labware		72,024		71,798	0.3
TOTAL	$	217,653	$	205,349	6.0
TOTAL UNITED STATES	$	1,574,001	$	1,474,644	6.7

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

Page 9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

	International
					% Change
		2008		2007	Reported	FX Neutral	FX Impact
BD MEDICAL
Medical Surgical Systems	$	494,336	$	441,909	11.9	2.5	9.4
Diabetes Care		181,438		151,738	19.6	8.4	11.2
Pharmaceutical Systems		333,623		294,483	13.3	1.8	11.5
Ophthalmic Systems		26,367		21,665	21.7	11.1	10.6
TOTAL	$	1,035,764	$	909,795	13.8	3.4	10.4
BD DIAGNOSTICS
Preanalytical Systems	$	261,687	$	221,179	18.3	7.5	10.8
Diagnostic Systems		231,060		185,753	24.4	14.5	9.9
TOTAL	$	492,747	$	406,932	21.1	10.7	10.4
BD BIOSCIENCES
Cell Analysis (1)	$	279,205	$	223,652	24.8	14.4	10.4
Discovery Labware		70,975		62,426	13.7	3.7	10.0
TOTAL	$	350,180	$	286,078	22.4	12.0	10.4
TOTAL INTERNATIONAL	$	1,878,691	$	1,602,805	17.2	6.8	10.4

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

Page 10

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

	Total
					% Change
		2008		2007	Reported	FX Neutral	FX Impact
BD MEDICAL
Medical Surgical Systems	$	979,528	$	915,092	7.0	2.5	4.5
Diabetes Care		376,847		339,877	10.9	5.9	5.0
Pharmaceutical Systems		436,380		381,752	14.3	5.4	8.9
Ophthalmic Systems		38,781		33,670	15.2	8.4	6.8
TOTAL	$	1,831,536	$	1,670,391	9.6	4.0	5.6
BD DIAGNOSTICS
Preanalytical Systems	$	545,661	$	484,819	12.5	7.6	4.9
Diagnostic Systems		507,662		430,812	17.8	13.6	4.2
TOTAL	$	1,053,323	$	915,631	15.0	10.4	4.6
BD BIOSCIENCES
Cell Analysis (1)	$	424,834	$	357,203	18.9	12.4	6.5
Discovery Labware		142,999		134,224	6.5	1.9	4.6
TOTAL	$	567,833	$	491,427	15.5	9.5	6.0
TOTAL REVENUES	$	3,452,692	$	3,077,449	12.2	6.8	5.4

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

Page 11